1 Duquesne University, Graduate School of Pharmaceutical Sciences, Pittsburgh, PA, USA.
2 GlaxoSmithKline, Analytical Science and Development, King of Prussia, PA, USA.
Appl Spectrosc. 2017 Aug;71(8):1856-1867. doi: 10.1177/0003702817690407. Epub 2017 Mar 30.
Polymorph detection is critical for ensuring pharmaceutical product quality in drug substances exhibiting polymorphism. Conventional analytical techniques such as X-ray powder diffraction and solid-state nuclear magnetic resonance are utilized primarily for characterizing the presence and identity of specific polymorphs in a sample. These techniques have encountered challenges in analyzing the constitution of polymorphs in the presence of other components commonly found in pharmaceutical dosage forms. Laborious sample preparation procedures are usually required to achieve satisfactory data interpretability. There is a need for alternative techniques capable of probing pharmaceutical dosage forms rapidly and nondestructively, which is dictated by the practical requirements of applications such as quality monitoring on production lines or when quantifying product shelf lifetime. The sensitivity of transmission Raman spectroscopy for detecting polymorphs in final tablet cores was investigated in this work. Carbamazepine was chosen as a model drug, polymorph form III is the commercial form, whereas form I is an undesired polymorph that requires effective detection. The concentration of form I in a direct compression tablet formulation containing 20% w/w of carbamazepine, 74.00% w/w of fillers (mannitol and microcrystalline cellulose), and 6% w/w of croscarmellose sodium, silicon dioxide, and magnesium stearate was estimated using transmission Raman spectroscopy. Quantitative models were generated and optimized using multivariate regression and data preprocessing. Prediction uncertainty was estimated for each validation sample by accounting for all the main variables contributing to the prediction. Multivariate detection limits were calculated based on statistical hypothesis testing. The transmission Raman spectroscopic model had an absolute prediction error of 0.241% w/w for the independent validation set. The method detection limit was estimated at 1.31% w/w. The results demonstrated that transmission Raman spectroscopy is a sensitive tool for polymorphs detection in pharmaceutical tablets.
多晶型检测对于确保具有多晶型现象的药物原料药的药品质量至关重要。传统的分析技术,如 X 射线粉末衍射和固态核磁共振,主要用于表征样品中特定多晶型的存在和身份。这些技术在分析药物剂型中常见的其他成分存在时的多晶型组成方面遇到了挑战。通常需要繁琐的样品制备程序才能实现令人满意的数据可解释性。需要替代技术,能够快速、非破坏性地探测药物剂型,这是应用的实际要求所决定的,例如生产线质量监测或量化产品保质期。本工作研究了传输拉曼光谱在检测最终片剂核心中多晶型的灵敏度。卡马西平被选为模型药物,形式 III 是商业形式,而形式 I 是需要有效检测的不期望多晶型。在含有 20%w/w 卡马西平、74.00%w/w 赋形剂(甘露醇和微晶纤维素)和 6%w/w 交联羧甲基纤维素钠、二氧化硅和硬脂酸镁的直接压片配方中,使用传输拉曼光谱估计形式 I 的浓度。使用多元回归和数据预处理生成和优化定量模型。通过考虑所有对预测有贡献的主要变量,为每个验证样本估计预测不确定性。基于统计假设检验计算多变量检测限。传输拉曼光谱模型对独立验证集的绝对预测误差为 0.241%w/w。方法检测限估计为 1.31%w/w。结果表明,传输拉曼光谱是探测药物片剂中多晶型的敏感工具。